Enliven Therapeutics, Inc. Common Stock
ELVN
$46.13
+14.30%
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for oncology, primarily targeting chronic myeloid leukemia (CML) and HER2-driven cancers. The company is a pre-revenue, development-stage biotech player, distinguished by its pipeline assets ELVN-001, a BCR-ABL inhibitor, and ELVN-002, a HER2 inhibitor. The current investor narrative is overwhelmingly driven by positive clinical data readouts, as evidenced by the stock's dramatic surge in late March 2026, which has propelled the stock to multi-year highs and solidified a story of potential breakthrough efficacy for its lead candidates.…
ELVN
Enliven Therapeutics, Inc. Common Stock
$46.13
Investment Opinion: Should I buy ELVN Today?
Rating: Hold. The core thesis is that while Enliven's clinical data is promising and has justifiably driven a major re-rating, the stock now prices in near-perfect execution, leaving minimal margin for error and an unfavorable risk/reward profile at current levels.
Supporting this Hold rating are several data points: the stock trades at a massive 97% of its 52-week high after a +203.96% run, indicating extreme optimism. It is a pre-revenue company with a forward P/S multiple that is incalculable but implied to be high based on a $2.58B market cap versus $316.5M in estimated future revenue. While the balance sheet is strong (D/E of 0.0009), cash burn is heavy at -$70.46M TTM FCF. Specialist analyst sentiment is positive but coverage is limited to only two firms, reducing visibility.
The thesis would upgrade to a Buy if the stock experiences a healthy pullback (e.g., to the $30-$35 range) on non-fundamental news, providing a better entry point ahead of the next clinical catalyst, or if subsequent trial data exceeds already-high expectations. It would downgrade to a Sell if clinical development stalls, cash burn accelerates unexpectedly, or the stock breaks below key technical support near $38. Relative to its own history and the binary risk profile, the stock is overvalued, as the market is pricing in a high probability of unblemished clinical and commercial success.
Sign up to view all
ELVN 12-Month Price Forecast
The AI assessment is neutral based on the extreme asymmetry of outcomes. The bullish clinical narrative is powerful but now fully reflected in the price, leaving the stock vulnerable to any disappointment. The strong balance sheet provides a runway, but the cash burn necessitates future dilution. The stance would upgrade to bullish on a significant pullback that improves the risk/reward, or on unequivocally positive clinical data. It would downgrade to bearish on a breakdown of key technical support or any negative clinical development. For now, the prudent view is to wait for a better entry point or clearer de-risking of the pipeline.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Enliven Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $59.97 and implied upside of +30.0% versus the current price.
Average Target
$59.97
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$37 - $60
Analyst target range
Insufficient analyst coverage available. Only two analysts provide estimates for the company, and the provided data does not include a consensus price target or Buy/Hold/Sell distribution. This limited coverage is typical for a small to mid-cap, clinical-stage biotech like Enliven and implies higher volatility and less efficient price discovery, as the stock is more susceptible to moves driven by binary clinical data and specialist investor sentiment rather than broad Wall Street analysis. The institutional ratings data shows a pattern of consistently bullish actions, with recent reiterations of 'Buy' and 'Outperform' ratings from firms like HC Wainwright and Mizuho in March 2026, coinciding with the stock's major price surge, indicating strong specialist support for the recent clinical developments.
Bulls vs Bears: ELVN Investment Factors
The evidence is currently balanced but tilted towards the bulls due to the powerful, data-driven price momentum and strong specialist backing. However, the bull case is built on highly speculative future success, while the bear case is grounded in present financial reality and technical overextension. The single most important tension in the investment debate is the clash between the validated clinical promise (driving the rally) and the unsustainable valuation for a pre-revenue company facing years of cash burn and binary clinical risk. The resolution of upcoming clinical trial milestones will determine which narrative prevails.
Bullish
- Explosive Clinical Data Rally: The stock has surged +203.96% over the past year, with a +47.62% gain in the past month, driven by positive clinical data readouts for its lead candidates ELVN-001 and ELVN-002. This momentum, far outpacing the S&P 500, signals strong specialist investor conviction in the pipeline's potential breakthrough efficacy.
- Robust Balance Sheet for Development: The company has a fortress balance sheet with a current ratio of 28.66 and a negligible debt-to-equity ratio of 0.0009. This provides ample liquidity to fund ongoing clinical trials for its two lead oncology assets without immediate financial distress, a critical advantage for a pre-revenue biotech.
- Strong Specialist Analyst Support: Despite limited broad coverage, institutional analysts from firms like HC Wainwright and Mizuho reiterated 'Buy' and 'Outperform' ratings in March 2026, coinciding with the stock's major surge. This specialist support validates the clinical narrative and provides a degree of credibility to the investment thesis.
- Valuation Not Extreme vs. Book Value: The current Price/Book ratio of 1.90 is near the middle of its observed historical range (0.52 to 4.27). This suggests the $2.58 billion market cap is not detached from the company's tangible equity base, which is largely comprised of cash from prior financings, providing a fundamental anchor.
Bearish
- Pre-Revenue with Heavy Cash Burn: Enliven has zero revenue and reported a net loss of -$29.67 million in Q4 2025. With a trailing twelve-month free cash flow of -$70.46 million, the company is burning significant cash and will require additional dilutive capital raises long before achieving profitability.
- Extreme Technical Overextension: The stock trades at $45.32, which is 97% of the way to its 52-week high of $46.30 from a low of $14.45. This parabolic +203.96% one-year move, coupled with a +74.31% three-month surge, indicates extreme momentum that is vulnerable to sharp profit-taking and a significant technical correction.
- Binary Pipeline Risk: The entire $2.58 billion valuation hinges on the success of just two clinical-stage assets, ELVN-001 and ELVN-002. Any clinical setback, regulatory delay, or competitive threat in the CML or HER2 spaces could erase a substantial portion of the market cap, as seen in the stock's historical -36.84% max drawdown.
- Limited Analyst Coverage & Visibility: Only two analysts provide estimates for the company, resulting in poor price discovery and higher volatility. The lack of a consensus price target or detailed financial forecasts increases uncertainty and makes the stock more susceptible to sentiment swings rather than fundamental analysis.
ELVN Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +203.96%. As of the latest close at $45.32, the stock is trading near the top of its 52-week range, approximately 97% of the way from its 52-week low of $14.45 to its high of $46.30, indicating extreme momentum and potential overextension in the near term. Recent momentum has been explosive, with the stock surging +47.62% over the past month and +74.31% over the past three months, far outpacing the S&P 500's returns of +0.46% and -2.1%, respectively, over the same periods; this divergence from the broader market and acceleration from the longer-term trend signals a stock-specific, catalyst-driven rally, likely fueled by recent positive clinical data. Key technical levels are clear, with immediate resistance at the 52-week high of $46.30 and support far below near the $14.45 low; a breakout above $46.30 would signal a continuation of the bullish trend, while a breakdown below the recent consolidation zone around $38-$40 could indicate profit-taking. The stock's beta of 0.491 suggests it has been significantly less volatile than the market during this data period, but this low beta is likely distorted by its extended pre-catalyst trading range and does not reflect the extreme volatility exhibited during the recent news-driven surge.
Beta
0.40
0.40x market volatility
Max Drawdown
-36.8%
Largest decline past year
52-Week Range
$15-$49
Price range past year
Annual Return
+134.6%
Cumulative gain past year
| Period | ELVN Return | S&P 500 |
|---|---|---|
| 1m | +5.9% | -0.1% |
| 3m | +66.1% | +12.0% |
| 6m | +173.6% | +8.8% |
| 1y | +134.6% | +22.9% |
| ytd | +196.8% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELVN Fundamental Analysis
As a clinical-stage biotech, Enliven has no commercial revenue, with quarterly revenue consistently reported as $0; the investment case is entirely predicated on the future potential of its pipeline, with the latest estimated annual revenue from analysts at $316.5 million, reflecting expectations for future commercialization. The company is deeply unprofitable, reporting a net income of -$29.67 million and an EPS of -$0.45 for Q4 2025, with gross profit negative at -$46,000 due to minimal cost of revenue; losses have been persistent but show some quarterly variability, with net income improving from -$28.54 million in Q1 2025 to -$20.15 million in Q3 2025 before widening again in Q4, indicating ongoing heavy investment in research and development, which totaled $21.25 million in the latest quarter. The balance sheet remains strong for a development-stage company, with a robust current ratio of 28.66 and a minimal debt-to-equity ratio of 0.0009, indicating ample liquidity and negligible leverage; however, cash flow is heavily negative, with operating cash flow of -$15.84 million and free cash flow of -$70.46 million (TTM), meaning the company is burning significant cash to fund its clinical trials and will likely require additional capital raises before achieving profitability.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-70459000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELVN Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio, but with zero current revenue, the trailing PS ratio is 0. The forward-looking valuation hinges entirely on future sales estimates, with analyst consensus revenue for the next fiscal year at $316.5 million, implying a forward Price/Sales multiple based on the current market cap; however, without a current PS multiple, peer comparison on this basis is not meaningful from the provided data, though the stock's market cap of ~$2.58 billion reflects a high implied valuation for a pre-revenue company, betting heavily on clinical success. Historically, the stock's valuation has been inapplicable on a sales basis, but its Price/Book ratio of 1.90 is near the middle of its historical range observed in the data (from 0.52 to 4.27), suggesting the current market cap is not extreme relative to the company's equity base, though the book value is largely comprised of cash from prior financings.
PE
-8.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -16x~-1x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and inherent to Enliven's stage. The company is pre-revenue, burning cash at a rate of -$70.46 million (TTM FCF), and reported a net loss of -$29.67 million last quarter. With only 60 employees and a pipeline of two assets, revenue concentration risk is absolute; failure of either ELVN-001 or ELVN-002 would be catastrophic. The strong balance sheet (current ratio 28.66) mitigates near-term liquidity risk but does not eliminate the high probability of future dilutive equity offerings to fund operations through clinical development.
Market & Competitive Risks are elevated. The stock's +203.96% year-over-year surge has created extreme valuation compression risk; any disappointment could trigger a violent de-rating. Trading at 97% of its 52-week high, the stock is technically overextended and vulnerable to sector rotation out of high-risk biotech. Competitive disruption in the crowded CML and HER2 inhibitor markets is a constant threat. The stock's low beta of 0.491 is misleading, as it reflects past tranquility, not the extreme volatility exhibited during recent clinical catalyst events.
Worst-Case Scenario involves a material clinical setback for a lead candidate, such as failed efficacy in a pivotal trial or a serious safety issue. This would likely trigger a cascade of analyst downgrades, a loss of specialist investor support, and a flight to safety. Given the stock's reliance on future promise, a re-rating back towards its tangible book value or pre-catalyst trading levels is plausible. A realistic downside could see the stock fall -68% to retest its 52-week low of $14.45, representing a loss of over two-thirds of its current value from $45.32.
FAQ
The key risks are, in order of severity: 1) Clinical Failure Risk: The entire valuation depends on two pipeline assets; a trial failure could erase most of the stock's value (max drawdown -36.84% historically). 2) Financial Risk: The company is pre-revenue with a -$70.46M TTM free cash flow burn, necessitating future dilutive capital raises. 3) Valuation & Technical Risk: After a +204% surge, the stock is extremely overbought and prone to a sharp correction on any negative news. 4) Competitive & Market Risk: The CML and HER2 spaces are competitive, and broader biotech sentiment can heavily influence the stock independent of company-specific news.
The 12-month forecast is highly bifurcated, with three distinct scenarios. The Base Case (50% probability) sees the stock consolidating between $35 and $45 as it digests its massive gains. The Bull Case (25% probability), driven by stellar clinical data, could propel the stock to $50-$65. The Bear Case (25% probability), triggered by a clinical setback, could see a collapse back towards the $14.45 low, with a range of $14-$30. The most likely outcome is the Base Case of volatile consolidation, as the stock transitions from a pure data-trading vehicle to a story awaiting further de-risking events.
ELVN is overvalued based on traditional financial metrics, as it has no revenue, negative earnings, and a high cash burn. Its $2.58 billion market cap is a bet on future sales estimated at $316.5 million. The Price/Book ratio of 1.90 is reasonable but reflects a cash-rich balance sheet, not operating assets. The market is paying a significant premium for unproven clinical promise. Compared to its own history, the stock is at the upper end of its valuation range following the recent rally, implying the market expects flawless clinical development and successful commercialization.
ELVN is not a good buy for most investors at its current price of $45.32. The stock has already surged +204% in a year and trades at 97% of its 52-week high, pricing in a high degree of clinical success. For a pre-revenue company burning over $70M annually in cash, the risk/reward is unfavorable. It could be a good buy for a highly specialized, risk-seeking investor on a significant pullback (e.g., towards $30) or following another piece of unequivocally positive clinical data that de-risks the pipeline further. For the average investor, it is a speculative hold at best.
ELVN is unsuitable for short-term trading for all but the most sophisticated traders due to its binary, news-driven volatility and low analyst coverage. It is a long-term, speculative investment for those willing to hold through multiple clinical trial phases, potential dilution events, and extreme price swings. The investment horizon should be a minimum of 3-5 years to see through key clinical readouts and the path towards potential commercialization. Given the lack of dividends and high beta (despite a reported 0.491, recent action shows high volatility), it serves no role in an income or low-volatility portfolio.